相关实验视频

Updated: Jul 6, 2025

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

在实验NS中由葡萄糖皮质醇和皮奥格利塔诱导的蛋白尿减少,都与球ECM调节相关

Sagar Bhayana¹, Julie A Dougherty¹, Yu Kamigaki¹

¹Center for Clinical and Translational Research, The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH 43205, USA.

|January 8, 2024

概括

葡萄糖皮质类药物和皮奥格利塔通过重叠基因表达来降低脏综合征 (NS) 中的蛋白尿,特别是在细胞外矩阵重塑中. 这表明,向ECM可能为NS提供新的非免疫抑制治疗方法.

科学领域:

腎臟病學 (nephrology) 是一種醫學.
基因组学就是基因组学.
系统生物学系统生物学

背景情况:

异常性性综合征 (NS) 是一种常见的淋巴细胞疾病.
葡萄糖皮质类药物 (GC) 是标准的治疗方法,但PPARγ激动剂皮奥利塔 (Pio) 也可以减少蛋白尿并保护皮细胞.
共同的治疗效果表明重叠的分子机制.

研究的目的:

为了比较GC和Pio在脏综合征中的转录效应.
为了确定两种药物所准的共同分子通路.
探索NS的潜在非免疫抑制治疗策略.

主要方法:

在PAN诱导的NS的老鼠模型中,对球转录组的系统生物学分析.
在GC和Pio治疗的老鼠之间比较基因表达模式.
在体细胞解过程中,以确定细胞特异性基因调控.
与临床异常性NS患者数据的相关性.

主要成果:

确定了29个常规调节的基因,主要涉及到细胞外矩阵 (ECM) 改造.
证实了质ECM失调作为临床NS的潜在机制.
表明GC和Pio都能改善受体细胞和介质细胞中改变的基因表达.

结论:

GC和Pio在NS中施加重叠的转录效应,重点是ECM重塑.
向淋巴细胞ECM失调可能为减少NS蛋白尿症提供未来的非免疫抑制方法.
这些发现突出了早期NS所涉及的途径,先于不可逆转的痕.

关键词:

基因网络基因网络腎臟病學 (nephrology) 是一種醫學.系统生物学系统生物学文字转录学 (Transcriptomics) 是一个学科.

更多相关视频

Fabricating a Kidney Cortex Extracellular Matrix-Derived Hydrogel

Fabricating a Kidney Cortex Extracellular Matrix-Derived Hydrogel

Published on: October 13, 2018

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

相关概念视频

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...